{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:08:30Z","timestamp":1790712510849,"version":"4.1.0"},"reference-count":41,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["821511"],"award-info":[{"award-number":["821511"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic inflammatory skin diseases such as atopic dermatitis (AD) and psoriasis (PSO) present major challenges in health care. Thus, biomarkers to identify disease trajectories and response to treatments to improve the lives of affected individuals warrant great research consideration. The requirements that these biomarkers must fulfil for use as practical clinical tools have not yet been adequately investigated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To identify the core elements of high\u2010quality AD and PSO biomarkers to prepare recommendations for current biomarker research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A cross\u2010sectional two\u2010round Delphi survey was conducted from August to October 2019 and October to November 2020. All participants were members of the BIOMAP project, an EU\u2010funded consortium of clinicians, researchers, patient organizations and pharmaceutical industry partners. The first round consisted of three open\u2010ended questions. Responses were qualitatively analysed, and 26 closed statements were developed. For the second round, \u2018agreement\u2019 was assumed when the responses of \u226570% of the participants were \u22655 points on a 7\u2010point Likert scale for each statement. Priority classification was based on mean scores (&lt;20th percentile\u2009=\u2009low, 20th to 60th percentile\u2009=\u2009medium, &gt;60th percentile\u2009=\u2009high).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty\u2010one and twenty\u2010six individuals participated in rounds one and two, respectively. From 26 statements that were included in round 2, 18 achieved agreement (8 concerning the performance, 8 for the purpose and 2 on current obstacles). Seven statements were classified as high priority, e.g. those concerning reliability, clinical validity, a high positive predictive value, prediction of the therapeutic response and disease progression. Another seven statements were assigned medium priority, e.g. those about analytical validity, prediction of comorbidities and therapeutic algorithm. Low priority included four statements, like those concerning cost effectiveness and prediction of disease flares.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The core requirements that experts agreed on being essential for high\u2010quality AD and PSO biomarkers require rapid validation. Biomarkers can therefore be assessed based on these prioritized requirements.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.18178","type":"journal-article","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T01:13:51Z","timestamp":1650935631000},"page":"1467-1476","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Requirements and expectations of high\u2010quality biomarkers for atopic dermatitis and psoriasis in 2021\u2014a two\u2010round Delphi survey among international experts"],"prefix":"10.1111","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3176-1120","authenticated-orcid":false,"given":"S.","family":"Ziehfreund","sequence":"first","affiliation":[{"name":"Department of Dermatology and Allergy Technical University of Munich, School of Medicine  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2749-9791","authenticated-orcid":false,"given":"L.","family":"Tizek","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy Technical University of Munich, School of Medicine  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6809-4603","authenticated-orcid":false,"given":"N.","family":"Hangel","sequence":"additional","affiliation":[{"name":"Institute for History and Ethics of Medicine Technical University of Munich  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.\u2010C.","family":"Fritzsche","sequence":"additional","affiliation":[{"name":"Institute for History and Ethics of Medicine Technical University of Munich  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Weidinger","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy University Hospital Schleswig\u2010Holstein  Kiel Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9918-1144","authenticated-orcid":false,"given":"C.","family":"Smith","sequence":"additional","affiliation":[{"name":"St John's Institute of Dermatology Kings College London and Guys and St Thomas' NHS Foundation Trust Guy's Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.J.","family":"Bryce","sequence":"additional","affiliation":[{"name":"Type 2 Inflammation &amp; Fibrosis Cluster Immunology &amp; Inflammation Therapeutic Area, Sanofi US  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Greco","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Technology, BioMediTech Institute Tampere University  Tampere Finland"},{"name":"Institute of Biotechnology, Helsinki Institute for Life Science (HiLife) University of Helsinki  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.H.","family":"van den Bogaard","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Radboud University Medical Center Radboud Institute for Molecular Life Sciences  Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4884-6286","authenticated-orcid":false,"given":"C.","family":"Flohr","sequence":"additional","affiliation":[{"name":"Unit for Population\u2010Based Dermatology Research St John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Rastrick (UCB)","sequence":"additional","affiliation":[{"name":"Immunology Research New Medicines UCB Pharma  Slough UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Eyerich","sequence":"additional","affiliation":[{"name":"Center of Allergy and Environment (ZAUM) Technical University and Helmholtz Center Munich  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Buyx","sequence":"additional","affiliation":[{"name":"Institute for History and Ethics of Medicine Technical University of Munich  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2547-3440","authenticated-orcid":false,"given":"C.","family":"Conrad","sequence":"additional","affiliation":[{"name":"Department of Dermatology Lausanne University Hospital CHUV  Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Eyerich","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy Technical University of Munich, School of Medicine  Munich Germany"},{"name":"Division of Dermatology and Venerology, Department of Medicine Solna Karolinska Institutet  Stockholm Sweden"},{"name":"Department of Dermatology and Venereology, Medical Center University of Freiburg  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9313-6588","authenticated-orcid":false,"given":"A.","family":"Zink","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy Technical University of Munich, School of Medicine  Munich Germany"},{"name":"Division of Dermatology and Venerology, Department of Medicine Solna Karolinska Institutet  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,5,17]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19580"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19169"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2018.05.007"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.05.1241"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13320"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3510"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13854"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132454"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14673"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0001-z"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.82"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.02.017"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14864"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17110"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15634"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3102"},{"key":"e_1_2_8_18_1","volume-title":"Biomarkers in Risk Assessment: Validity and Validation","author":"World Health Organication & International Programme on chemical safety","year":"2001"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.01.013"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02545-4"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14557"},{"key":"e_1_2_8_22_1","unstructured":"Biomap.About BIOMAP. Towards Personalised Medicine for Inflamatory Skin Diseases. URL:https:\/\/biomap\u2010imi.eu\/about(last accessed 15 November2021)"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/9783527622153.ch33"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.5292"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/0962280207082719"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2012.01.010"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(03)00211-7"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2648.2000.t01-1-01567.x"},{"key":"e_1_2_8_29_1","volume-title":"BEST (biomarkers, EndpointS, and other tools) Recource [internet]","author":"FDA\u2010NIH Biomarker Working Group","year":"2016"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/030802269806100403"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.11.047"},{"key":"e_1_2_8_32_1","unstructured":"PsoBest.Das Deutsche Psoriasis\u2010Register. URL:https:\/\/www.psobest.de\/das\u2010register\/(last accessed 15 November 2021)."},{"key":"e_1_2_8_33_1","unstructured":"TREATgermany.Deutsches Neurodermitis\u2010Register. URL:http:\/\/www.treatgermany.org(last accessed 15 November 2021)."},{"key":"e_1_2_8_34_1","unstructured":"MAPS.Munich Atopy Prediction Study. URL:https:\/\/www.mri.tum.de\/dermatologie(last accessed 15 November 2021)."},{"key":"e_1_2_8_35_1","unstructured":"The BIOMAP Consortium.BIOMAP glossary. URL:https:\/\/zenodo.org\/record\/4746584#.YPanEy1Q1MM(last accessed 15 November 2021)."},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20587"},{"key":"e_1_2_8_37_1","volume-title":"Optimizing oncology care through biomarker adoption: BARRIERS AND SOLUTIONS","author":"Aitken M","year":"2020"},{"key":"e_1_2_8_38_1","first-page":"101","article-title":"Using Delphi to achieve congruent objectives and activities in a pediatrics department","volume":"54","author":"Loughlin KG","year":"1979","journal-title":"J Med Educ"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2648.2006.03716.x"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2648.1994.tb01066.x"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0020-7489(00)00044-4"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/0040-1625(79)90011-8"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18178","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.18178","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18178","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T03:32:52Z","timestamp":1721619172000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.18178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,17]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1111\/jdv.18178"],"URL":"https:\/\/doi.org\/10.1111\/jdv.18178","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,17]]},"assertion":[{"value":"2021-12-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}